Chemours Co reported first quarter 2026 results: revenue $1.4 billion, net income Net Loss attributable to Chemours of $29 million, or $0.19 per diluted share, EPS $0.19 per diluted share.
“and Advanced Performance Materials (“APM”), today announced its financial results for the first quarter 2026. Key First Quarter 2026 Results & Recent Highlights 1 • Net Sales of $1.4 billion, slightly up compared to the corresponding prior-year quarter, with TSS reporting record first quarter results, with continued double-digit year-over-year sales growth in”
Material Agreements
Chemours Co entered into Purchase Agreements with Century Wind Power Co., Ltd., Century Iron and Steel Industrial Co., Ltd., Century Huaxin Wind Energy Co., Ltd. and Mr. Lai Wen-Hsiang valued at approximately $360 million (effective 2026-01-15).
“On January 15, 2026 (the “Effective Date”), The Chemours Company (the “Company”), through its subsidiary, The Chemours (Taiwan) Company Limited (“Seller”), entered into four separate Real Estate Sale and Purchase Agreements (collectively, the “Purchase Agreements”) with four affiliated entities: Century Wind Power Co., Ltd., Century Iron and Steel Industrial Co., Ltd., Century Huaxin Wind Energy Co., Ltd. and Mr. Lai Wen-Hsiang (collectively, the “Buyers”) to sell ten parcels of land in Kuan Yin, Taiwan (collectively, the “Property”) for a total purchase price of approximately $360 million.”
Debt Financings
Chemours Co amended term loan of $1,050,000,000 with JPMorgan Chase Bank, N.A., as administrative agent at adjusted Term SOFR + 3.50% or adjusted base rate plus 2.50% maturing October 15, 2032.
“The Amendment extended the maturity date of the Company’s $1,050,000,000 senior secured U.S. dollar-denominated term loan facility (the “Term Loan B-3 US$ Facility”) from August 18, 2028 to October 15, 2032.”
Guillaume Pepy departed as Director at Chemours Co.
“On March 9, 2025, Guillaume Pepy notified the Board of Directors (the “Board”) of The Chemours Company (the “Company”) of his decision not to seek re-election to the Board at the Company’s 2025 Annual Meeting of Shareholders, when his current term expires.”
Curtis V. Anastasio departed as Director at Chemours Co.
“On February 13, 2025, Curtis V. Anastasio notified the Board of Directors (the "Board") of The Chemours Company (the "Company") of his decision not to seek re-election to the Board at the Company's 2025 Annual Meeting of Stockholders, when his current term expires.”
Leslie M. Turner was appointed as member of the Board at Chemours Co.
“appointed Leslie M. Turner as a member of the Board, effective February 19, 2025.”
Joseph D. Kava was appointed as member of the Board at Chemours Co.
“On January 3, 2025, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Joseph D. Kava as a member of the Board, effective January 3, 2025.”
David A. Will was appointed as Controller and Chief Accounting Officer at Chemours Co.
“On July 23, 2024, David A. Will was appointed as Controller and Chief Accounting Officer (principal accounting officer) of The Chemours Company (the “Company”) effective as of August 12, 2024.”
Livingston "Tony" Satterthwaite was appointed as Director at Chemours Co.
“On June 12, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Livingston “Tony” Satterthwaite as a member of the Board, effective June 12, 2024.”
Matthew Abbott changed role as Senior Vice President & Chief Enterprise Transformation Officer at Chemours Co.
“Mr. Hostetter succeeds Matthew Abbott, who has served as the Interim Chief Financial Officer (principal financial and accounting officer) since February 28, 2024. Mr. Abbott will continue serving as the Company’s Senior Vice President & Chief Enterprise Transformation Officer”
Shane Hostetter was appointed as Chief Financial Officer at Chemours Co.
“On May 31, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Shane Hostetter as Chief Financial Officer, effective as of July 1, 2024.”
Earnings Releases
Chemours Co reported first quarter 2024 results: revenue $1.4 billion, net income $52 million, or $0.34 per diluted share, EPS $0.34 per diluted share.
“Solutions (“TSS”), and Advanced Performance Materials (“APM”), today announced its financial results for the first quarter 2024. Key First Quarter 2024 Results • Net Sales of $1.4 billion, down 12% year-over-year • Net Income attributable to Chemours of $52 million, or $0.34 per diluted share, compared with $145 million, or $0.96 per diluted share, in the”
Jonathan S. Lock resigned as Senior Vice President and Chief Financial Officer at Chemours Co.
“On April 23, 2024, Jonathan S. Lock resigned from all positions with The Chemours Company (the “Company”).”
Earnings Releases
Chemours Co reported fourth quarter and full year 2023 results: revenue Net Sales of $1.4 billion, net income Net Loss attributable to Chemours of $18 million, or a loss of $0.12 per diluted share, EPS Net Loss attributable to Chemours of $18 million, or a loss of $0.12 per diluted share.
“The Chemours Company Reports Fourth Quarter and Full Year 2023 Results Wilmington, Del., March 27, 2024 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies (“TT”), Thermal & Specialized Solutions (“TSS”), and Advanced Performance Materials (“APM”), today announced its financial results for the fourth quarter and full year 2023. Key Fourth Quarter 2023 Results • Net Sales of $1.4 billion, up 2% year-over-year • Net Loss attributable to Chemours of $18 million, or a loss of $0.12 per diluted share”
Mark Newman resigned as President and Chief Executive Officer at Chemours Co.
“Mark Newman, who resigned from his officer and director positions with the Company, also effective as of March 22, 2024.”
Denise Dignam was named as President and Chief Executive Officer at Chemours Co.
“The Board of Directors (the “Board”) of The Chemours Company (the “Company”) has named Denise Dignam, formerly Interim Chief Executive Officer, as President and Chief Executive Officer and as a member of the Board, effective as of March 22, 2024.”
Listing & Compliance Notices
Chemours Co received a nyse noncompliance notice notice regarding late filing (rules 802.01E).
“March 18, 2024, the New York Stock Exchange (the “NYSE”) notified The Chemours Company (the “Company”) that it is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”). In accordance with the NYSE Listed Company Manual, the Company has contacted the NYSE to discuss the status of its Form 10-K filing. On March 18, 2024, the Company issued a press release with respect to the receipt of the notice of noncompliance from the NYSE. A copy of the press rel”
Earnings Releases
Chemours Co reported year ended December 31, 2023 results: revenue approximately $6.0 billion, net income within a range of $(225) million to $(235) million.
“The Company expects to report net sales of approximately $6.0 billion for the year ended December 31, 2023, compared to net sales of $6.8 billion for the year ended December 31, 2022. The expected decrease was primarily attributable to lower volumes in Titanium Technologies and in Advanced Performance Materials’ Advanced Materials portfolio, partially offset by increased pricing and volumes in Thermal & Specialized Solutions. The Company expects to report net loss attributable to Chemours for the year ended December 31, 2023 within a range of $(225) million to $(235) million, compared to net income attributable to Chemours for the year ended December 31, 2022 of $578 million.”
Matthew Abbott was appointed as Interim Chief Financial Officer at Chemours Co.
“Matthew Abbott as the Interim Chief Financial Officer”
Denise Dignam was appointed as Interim Chief Executive Officer at Chemours Co.
“appointed Denise Dignam as the Interim Chief Executive Officer”
Camela Wisel departed as Vice President, Controller and Principal Accounting Officer at Chemours Co.
“the Board placed President and Chief Executive Officer Mark Newman, Senior Vice President and Chief Financial Officer Jonathan Lock and Vice President, Controller and Principal Accounting Officer Camela Wisel on administrative leave”
Jonathan Lock departed as Senior Vice President and Chief Financial Officer at Chemours Co.
“the Board placed President and Chief Executive Officer Mark Newman, Senior Vice President and Chief Financial Officer Jonathan Lock and Vice President, Controller and Principal Accounting Officer Camela Wisel on administrative leave”
Mark Newman departed as President and Chief Executive Officer at Chemours Co.
“the Board placed President and Chief Executive Officer Mark Newman, Senior Vice President and Chief Financial Officer Jonathan Lock and Vice President, Controller and Principal Accounting Officer Camela Wisel on administrative leave”
Pamela F. Fletcher was appointed as Director at Chemours Co.
“On February 13, 2024, the Board appointed Pamela F. Fletcher as a member of the Board, effective March 1, 2024.”
Sandra P. Rogers departed as Director at Chemours Co.
“On February 12, 2024, Sandra P. Rogers notified the Board of Directors (the “Board”) of The Chemours Company (the “Company”) of her decision not to seek re-election to the Board at the Company’s 2024 Annual Meeting of Stockholders, when her current term expires.”
Alister Cowan was appointed as Director at Chemours Co.
“On November 22, 2023, the Board appointed Alister Cowan BA, CA as a member of the Board.”
Curtis J. Crawford retired as Director at Chemours Co.
“On November 17, 2023, Curtis J. Crawford, Ph.D. notified the Board of Directors (the “Board”) of The Chemours Company (the “Company”) of his decision to retire from the Board effective November 22, 2023.”
Earnings Releases
Chemours Co reported third quarter 2023 results: revenue $1.5 billion, net income $20 million, EPS $0.13. Guidance lowered.
“(“APM”), today announced its financial results for the third quarter 2023, and Titanium Technologies Transformation Plan. Third Quarter 2023 Results & Highlights • Net Sales of $1.5 billion • Net Income of $20 million with EPS 1 of $0.13 • Adjusted Net Income 2 of $96 million with Adjusted EPS 2 of $0.63 • Adjusted EBITDA 2 of $247 million and Adjusted Free Cash”
Debt Financings
Chemours Co incurred term loan of €415,000,000 with JPMorgan Chase Bank, N.A., as administrative agent at adjusted EURIBOR plus 4.00%, subject to an adjusted EURIBOR floor of 0.0% maturing August 18, 2028.
“principal amount equal to $1,070,000,000 (the “Term Loan B-3 US$ Facility”), and a five-year senior secured term loan facility in an aggregate principal amount equal to €415,000,000 (the “Term Loan B-3 Euro Facility”). The Term Loan B-3 US$ Facility and the Term Loan B-3 Euro Facility are referred to collectively as the “New Term Loan Facilities.” The Tranche”
Debt Financings
Chemours Co incurred term loan of $1,070,000,000 with JPMorgan Chase Bank, N.A., as administrative agent at adjusted Term SOFR plus 3.50%, subject to an adjusted SOFR floor of 0.50%, or ad maturing August 18, 2028.
“commitments in an amount equal to $900,000,000 (the “Revolving Credit Facility”), a five-year, senior secured term loan facility in an aggregate principal amount equal to $1,070,000,000 (the “Term Loan B-3 US$ Facility”), and a five-year senior secured term loan facility in an aggregate principal amount equal to €415,000,000 (the “Term Loan B-3 Euro Facility”).”
Debt Financings
Chemours Co incurred revolving credit of $900,000,000 with JPMorgan Chase Bank, N.A., as administrative agent maturing October 7, 2026.
“The Restatement Agreement provides for a senior secured revolving credit facility with aggregate commitments in an amount equal to $900,000,000 (the “Revolving Credit Facility”)”
Material Agreements
Chemours Co entered into Amendment and Restatement Agreement with JPMorgan Chase Bank, N.A. valued at $900,000,000, $1,070,000,000, €415,000,000 (effective 2023-08-18).
“On August 18, 2023, The Chemours Company (the “Company”) entered into an Amendment and Restatement Agreement (the “Restatement Agreement”) among the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent, which amends and restates in its entirety the Amended and Restated Credit Agreement, dated as of April 3, 2018”
Earnings Releases
Chemours Co reported second quarter 2023 results: revenue $1.6 billion, net income Net Loss of $(376) million with EPS of $(2.52), EPS $(2.52). Guidance lowered.
“quarter 2023 paired with the announcement of the closing of the Kuan Yin, Taiwan titanium dioxide manufacturing facility. Second Quarter 2023 Results & Highlights • Net Sales of $1.6 billion • Net Loss of $(376) million with EPS 1 of $(2.52) • Adjusted Net Income 2 of $167 million with Adjusted EPS 2 of $1.10 • Adjusted EBITDA 2 of $324 million and Free Cash Flow of”
Restructurings & Charges
Chemours Co announced a restructuring with charges of approximately $150 million to $160 million affecting Titanium Technologies segment manufacturing site in Kuan Yin, Taiwan.
“As a result, in the third quarter 2023, the Company expects to record pre-tax asset-related impairment, restructuring, and other charges in the range of approximately $150 million to $160 million, comprised primarily of non-cash charges of approximately $130 million related to property, plant and equipment, inventory and other assets, and cash charges”
Matthew Abbott was appointed as Senior Vice President, Chief Enterprise Transformation Officer at Chemours Co.
“Matthew Abbott, Vice President, Digital and Data Analytics Leader, is appointed Senior Vice President, Chief Enterprise Transformation Officer, effective June 6, 2023.”
Jonathan Lock was appointed as Senior Vice President, Chief Financial Officer at Chemours Co.
“Jonathan Lock, Senior Vice President, Chief Development Officer is appointed Senior Vice President, Chief Financial Officer, effective June 6, 2023.”
Sameer Ralhan resigned as Senior Vice President at Chemours Co.
“Sameer Ralhan, Senior Vice President of The Chemours Company (the “Company”), notified the Company of his intention to resign, effective June 19, 2023.”
Material Agreements
Chemours Co entered into MOU with DuPont de Nemours, Inc., Corteva Inc., and EIDP, Inc. valued at $1.185 billion (effective 2023-06-01).
“On June 1, 2023, The Chemours Company (“Chemours”), The Chemours Company FC, LLC (“Chemours FC”), DuPont de Nemours, Inc. (“DuPont”), Corteva Inc. (“Corteva”) and E. I. du Pont de Nemours and Company n/k/a EIDP, Inc. (“E. I. du Pont” and, collectively with Chemours, Chemours FC, DuPont and Corteva, the “Companies”) entered into a binding agreement in principle (the “MOU”) to comprehensively resolve all drinking water claims related to per- and polyfluoroalkyl substances (as further clarified below, “PFAS”) of a defined class of U.S. public water systems that serve the vast majority of the United States population.”
Joseph T. Martinko was appointed as President, Thermal & Specialized Solutions at Chemours Co.
“Joseph T. Martinko the current Senior Business Director – Americas for Thermal & Specialized Solutions will assume Ms. Bellezza’s position on an interim basis effective June 1, 2023.”
Alisha Bellezza resigned as President, Thermal & Specialized Solutions at Chemours Co.
“On May 12, 2023, Alisha Bellezza, President, Thermal & Specialized Solutions of The Chemours Company (the “Company”), notified the Company of her intention to resign, effective May 31, 2023.”
Earnings Releases
Chemours Co reported first quarter 2023 results: revenue $1.5 billion, net income $145 million, EPS $0.96. Guidance reaffirmed.
“The Chemours Company Reports First Quarter 2023 Results Strong first quarter in Thermal & Specialized Solutions, company reaffirming full year 2023 Adjusted EBITDA and Free Cash Flow guidance Wilmington, Del ., April 27, 2023 -- The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies (TT), Thermal & Specialized Solutions (TSS), and Advanced Performance Materials (APM), today announced its financial results for the first quarter 2023. First Quarter 2023 Results & Highlights • Net Sales of $1.5 billion • Net Income of $145 million with EPS 1 of $0.96”
Shareholder Votes
Chemours Co shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-04-26 meeting.
“Proposal 3 – Ratification of Selection of Independent Registered Public Accounting Firm For Against Abstain Total Broker Non-Votes 128,403,641 (99.21%) 785,881 230,979 129,420,501 n/a”
Shareholder Votes
Chemours Co shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2023-04-26 meeting.
“Proposal 2 – Advisory Vote to Approve Named Executive Officer Compensation For Against Abstain Total Broker Non-Votes 106,793,855 (96.16%) 3,723,910 539,725 111,057,490 18,363,011”
Shareholder Votes
Chemours Co shareholders approved Election of Directors to Serve One-Year Term at the 2023-04-26 meeting.
“Proposal 1 – Election of Directors to Serve One-Year Term Nominee For Against Abstain Total Broker Non-Votes Curtis V. Anastasio 107,854,520 (97.12%) 2,733,970 469,009 111,057,499 18,363,002 Mary B. Cranston 108,395,830 (97.60%) 2,205,276 456,396 111,057,502 18,362,999 Curtis J. Crawford 109,633,207 (98.72%) 1,101,759 322,536 111,057,502 18,362,999 Dawn L. Farrell 109,835,964 (98.90%) 886,086 335,451 111,057,501 18,363,000 Erin N. Kane 109,501,453 (98.60%) 1,345,577 210,472 111,057,502 18,362,999 Sean D. Keohane 108,652,406 (97.83%) 1,937,892 467,202 111,057,500 18,363,001 Mark E. Newman 110,182,323 (99.21%) 550,858 324,320 111,057,501 18,363,000 Guillaume Pepy 108,385,679 (97.59%) 2,336,154 335,668 111,057,501 18,363,000 Sandra P. Rogers 108,911,475 (98.07%) 1,646,276 499,745 111,057,496 18,363,005”
Gerardo Familiar Calderon was appointed as President, Advanced Performance Materials at Chemours Co.
“In addition, Gerardo Familiar Calderon, the Company’s current Hydrogen Venture Leader, will become President, Advanced Performance Materials, effective April 1, 2023.”
Denise M. Dignam was appointed as President, Titanium Technologies and Chemical Solutions at Chemours Co.
“On March 23, 2023, the Chemours Company (the “Company”) issued a press release announcing that Denise M. Dignam, who serves as the Company’s President of Advanced Performance Materials, will become President, Titanium Technologies and Chemical Solutions, effective April 1, 2023.”
Edwin Sparks resigned as President – Titanium Technologies and Chemical Solutions at Chemours Co.
“On March 10, 2023, Edwin Sparks, President – Titanium Technologies and Chemical Solutions of The Chemours Company (the “Company”), notified the Company of his intention to resign, effective March 31, 2023.”
Debt Financings
Chemours Co amended credit facility with JPMorgan Chase Bank, N.A. at replaces the interest rate benchmark from the London Interbank Offered Rate (“LI.
“Amendment No. 2 replaces the interest rate benchmark from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”).”
Material Agreements
Chemours Co amended Amendment No. 2 with JPMorgan Chase Bank, N.A. (effective 2023-03-10).
“On March 10, 2023, The Chemours Company (the “Company”) entered into Amendment No. 2 (“Amendment No. 2”) to the Amended and Restated Credit Agreement, dated as of April 3, 2018, as amended on October 7, 2021, by and among the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Credit Agreement”).”
Earnings Releases
Chemours Co reported Full Year 2023 results: EPS ~$3.80 and $4.29. Guidance initiated.
“Full Year 2023 Outlook • Adjusted EBITDA * between $1.20 billion and $1.30 billion • Adjusted EPS * between ~$3.80 and $4.29”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.